ArticleInvestigative ophthalmology & visual science2026
Pharmacologic Alteration of Meibum Lipid Composition Alleviates Dry Eye Phenotype in Awat2-/- Mice.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Purpose: Meibomian glands (MGs) produce lipids that stabilize the tear film and maintain ocular surface homeostasis. Dysfunction of MG lipid secretion is a major cause of evaporative dry eye (EDE). The purpose of this study was to test whether pharmacologic modulation of meibum lipid biosynthesis could improve the physicochemical properties of meibum and thereby slow the progression of EDE in a mouse model of the disease. Methods: Awat2-/- mice, an animal model of EDE, were treated systemically with ATR101 (nevanimibe), a selective sterol O-acyltransferase 1 (SOAT1) inhibitor that suppresses cholesteryl ester (CE) synthesis. Meibum lipid composition, MG morphology, tear film breakup time, and corneal integrity were analyzed and compared with untreated controls to monitor disease progression. Results: Pharmacologic intervention in the CE biosynthesis in Awat2-/- mice altered the physicochemical properties of meibum, decreasing its melting temperature and increasing lipid fluidity. Treated mice exhibited reduced MG ductal obstruction and preservation of MG morphology. These changes were accompanied by prolonged tear film breakup time, improved tear film stability, and preserved corneal integrity compared with untreated Awat2-/- mice. Conclusions: Pharmacologic intervention in meibogenesis corrects a pathogenic lipid imbalance in Awat2-deficient MGs and improves tear film and MG function. These findings identify lipid metabolic remodeling of meibum as a mechanistically grounded therapeutic strategy for obstructive MG dysfunction and evaporative dry eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.